TY  - JOUR
AU  - Mussazhanova, Zhanna
AU  - Matsuda, Katsuya
AU  - Naruke, Yuki
AU  - Mitsutake, Norisato
AU  - Stanojević, Boban
AU  - Rougounovitch, Tatiana
AU  - Saenko, Vladimir
AU  - Suzuki, Keiji
AU  - Nishihara, Eijyun
AU  - Hirokawa, Mitsuyoshi
AU  - Ito, Masahiro
AU  - Nakashima, Masahiro
PY  - 2013
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/5717
AB  - AimsIn a previous report, we proposed that analysis of 53BP1 expression by immunofluorescence could be a useful tool in estimating the level of genomic instability (GIN), as well as the malignant potential, of thyroid tumours. In an attempt to clarify the value of 53BP1 expression as a new molecular marker for the aggressiveness of thyroid papillary microcarcinoma (PMC), we assessed the association between the type of 53BP1 expression and clinicopathological features such as tumour size, extrathyroidal invasion, lymph node metastasis and BRAF(V600E) mutation of PMC. Methods and resultsA total of 36 surgically resected thyroid tumours, including 13 PMC and 23 conventional papillary thyroid carcinomas (PTC), were available for this study. Analysis using immunofluorescence revealed that the incidence of an abnormal or high DNA damage response (DDR) type of 53BP1 expression was significantly higher in PTC than PMC. BRAF(V600E) mutation was not associated significantly with tumour aggressiveness in either PMC or PTC cases. Abnormal/high DDR type of 53BP1 expression was associated closely with both BRAF(V600E) mutation and papillary and/or trabecular architecture of PMC. ConclusionsAbnormal/high DDR type of 53BP1 expression might be associated with GIN and papillary/trabecular morphology at an early stage of PTC carcinogenesis through BRAF(V600E) mutation.
T2  - Histopathology
T1  - Significance of p53-binding protein 1 (53BP1) expression in thyroid papillary microcarcinoma: association with BRAF(V600E) mutation status
VL  - 63
IS  - 5
SP  - 726
EP  - 734
DO  - 10.1111/his.12233
ER  - 

@article{
author = "Mussazhanova, Zhanna and Matsuda, Katsuya and Naruke, Yuki and Mitsutake, Norisato and Stanojević, Boban and Rougounovitch, Tatiana and Saenko, Vladimir and Suzuki, Keiji and Nishihara, Eijyun and Hirokawa, Mitsuyoshi and Ito, Masahiro and Nakashima, Masahiro",
year = "2013",
abstract = "AimsIn a previous report, we proposed that analysis of 53BP1 expression by immunofluorescence could be a useful tool in estimating the level of genomic instability (GIN), as well as the malignant potential, of thyroid tumours. In an attempt to clarify the value of 53BP1 expression as a new molecular marker for the aggressiveness of thyroid papillary microcarcinoma (PMC), we assessed the association between the type of 53BP1 expression and clinicopathological features such as tumour size, extrathyroidal invasion, lymph node metastasis and BRAF(V600E) mutation of PMC. Methods and resultsA total of 36 surgically resected thyroid tumours, including 13 PMC and 23 conventional papillary thyroid carcinomas (PTC), were available for this study. Analysis using immunofluorescence revealed that the incidence of an abnormal or high DNA damage response (DDR) type of 53BP1 expression was significantly higher in PTC than PMC. BRAF(V600E) mutation was not associated significantly with tumour aggressiveness in either PMC or PTC cases. Abnormal/high DDR type of 53BP1 expression was associated closely with both BRAF(V600E) mutation and papillary and/or trabecular architecture of PMC. ConclusionsAbnormal/high DDR type of 53BP1 expression might be associated with GIN and papillary/trabecular morphology at an early stage of PTC carcinogenesis through BRAF(V600E) mutation.",
journal = "Histopathology",
title = "Significance of p53-binding protein 1 (53BP1) expression in thyroid papillary microcarcinoma: association with BRAF(V600E) mutation status",
volume = "63",
number = "5",
pages = "726-734",
doi = "10.1111/his.12233"
}

Mussazhanova, Z., Matsuda, K., Naruke, Y., Mitsutake, N., Stanojević, B., Rougounovitch, T., Saenko, V., Suzuki, K., Nishihara, E., Hirokawa, M., Ito, M.,& Nakashima, M.. (2013). Significance of p53-binding protein 1 (53BP1) expression in thyroid papillary microcarcinoma: association with BRAF(V600E) mutation status. in Histopathology, 63(5), 726-734.
https://doi.org/10.1111/his.12233

Mussazhanova Z, Matsuda K, Naruke Y, Mitsutake N, Stanojević B, Rougounovitch T, Saenko V, Suzuki K, Nishihara E, Hirokawa M, Ito M, Nakashima M. Significance of p53-binding protein 1 (53BP1) expression in thyroid papillary microcarcinoma: association with BRAF(V600E) mutation status. in Histopathology. 2013;63(5):726-734.
doi:10.1111/his.12233 .

Mussazhanova, Zhanna, Matsuda, Katsuya, Naruke, Yuki, Mitsutake, Norisato, Stanojević, Boban, Rougounovitch, Tatiana, Saenko, Vladimir, Suzuki, Keiji, Nishihara, Eijyun, Hirokawa, Mitsuyoshi, Ito, Masahiro, Nakashima, Masahiro, "Significance of p53-binding protein 1 (53BP1) expression in thyroid papillary microcarcinoma: association with BRAF(V600E) mutation status" in Histopathology, 63, no. 5 (2013):726-734,
https://doi.org/10.1111/his.12233 . .

TY  - JOUR
AU  - Stanojević, Boban
AU  - Džodić, Radan R.
AU  - Saenko, Vladimir
AU  - Milovanović, Zorka M.
AU  - Pupić, Gordana
AU  - Živković, Ognjen
AU  - Marković, Ivan
AU  - Đurišić, Igor
AU  - Buta, Marko
AU  - Dimitrijević, Bogomir B.
AU  - Rogounovitch, Tatiana
AU  - Mitsutake, Norisato
AU  - Mine, Mariko
AU  - Shibata, Yoshisada
AU  - Nakashima, Masahiro
AU  - Yamashita, Shunichi
PY  - 2011
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/4401
AB  - Molecular pathogenesis of papillary thyroid carcinoma (PTC) is largely associated with mutational changes in the BRAF, RAS family and RET genes. Our aim was to assess clinico-pathological and prognostic correlations of these PTC-specific gene alterations, with a particular emphasis on the BRAF mutation, in a group of 266 Serbian PTC patients, for the first time. The reference center-based retrospective cohort included 201 (75.6%) females and 65 (24.4%) males aged 48.0 +/- 16.1 years (8-83 years old, range) diagnosed and treated for PTC during 1993-2008. Follow-up period was 53.1 +/- 41.6 months (7-187 months, range). BRAF and RAS mutations were determined by direct sequencing of genomic DNA. RET/PTC rearrangements were analyzed by RT-PCR/Southern blotting. Genetic alterations were detected in 150/266 tumors (56.4%). One tumor displayed two genetic alterations. The BRAF(V600E) was found in 84/266 (31.6%) cases, RAS mutations in 11/266(4.1%) and RET/PTC in 55/266(20.7%; 42/266 (15.8%)RET/PTC1 and 13/266 (4.9%)RET/PTC3). On multivariate analysis BRAF(V600E) was associated with the classical papillary morphology (P = 0.05), the higher pT category (P = 0.05) and advanced clinical stage (P = 0.03). In a proportional hazard model, BRAF(V600E) did not appear to be an independent risk factor for the faster recurrence (P = 0.784). We conclude that under the extensive thyroid surgery and limited application of radioiodine ablation BRAF(V600E) may not be an indicator of poorer disease-free survival during the short to middle follow-up period. However, it has a potential to contribute to patients stratification into high- and low-risk groups.
T2  - Endocrine Journal
T1  - Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia
VL  - 58
IS  - 5
SP  - 381
EP  - 393
DO  - 10.1507/endocrj.K11E-054
ER  - 

@article{
author = "Stanojević, Boban and Džodić, Radan R. and Saenko, Vladimir and Milovanović, Zorka M. and Pupić, Gordana and Živković, Ognjen and Marković, Ivan and Đurišić, Igor and Buta, Marko and Dimitrijević, Bogomir B. and Rogounovitch, Tatiana and Mitsutake, Norisato and Mine, Mariko and Shibata, Yoshisada and Nakashima, Masahiro and Yamashita, Shunichi",
year = "2011",
abstract = "Molecular pathogenesis of papillary thyroid carcinoma (PTC) is largely associated with mutational changes in the BRAF, RAS family and RET genes. Our aim was to assess clinico-pathological and prognostic correlations of these PTC-specific gene alterations, with a particular emphasis on the BRAF mutation, in a group of 266 Serbian PTC patients, for the first time. The reference center-based retrospective cohort included 201 (75.6%) females and 65 (24.4%) males aged 48.0 +/- 16.1 years (8-83 years old, range) diagnosed and treated for PTC during 1993-2008. Follow-up period was 53.1 +/- 41.6 months (7-187 months, range). BRAF and RAS mutations were determined by direct sequencing of genomic DNA. RET/PTC rearrangements were analyzed by RT-PCR/Southern blotting. Genetic alterations were detected in 150/266 tumors (56.4%). One tumor displayed two genetic alterations. The BRAF(V600E) was found in 84/266 (31.6%) cases, RAS mutations in 11/266(4.1%) and RET/PTC in 55/266(20.7%; 42/266 (15.8%)RET/PTC1 and 13/266 (4.9%)RET/PTC3). On multivariate analysis BRAF(V600E) was associated with the classical papillary morphology (P = 0.05), the higher pT category (P = 0.05) and advanced clinical stage (P = 0.03). In a proportional hazard model, BRAF(V600E) did not appear to be an independent risk factor for the faster recurrence (P = 0.784). We conclude that under the extensive thyroid surgery and limited application of radioiodine ablation BRAF(V600E) may not be an indicator of poorer disease-free survival during the short to middle follow-up period. However, it has a potential to contribute to patients stratification into high- and low-risk groups.",
journal = "Endocrine Journal",
title = "Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia",
volume = "58",
number = "5",
pages = "381-393",
doi = "10.1507/endocrj.K11E-054"
}

Stanojević, B., Džodić, R. R., Saenko, V., Milovanović, Z. M., Pupić, G., Živković, O., Marković, I., Đurišić, I., Buta, M., Dimitrijević, B. B., Rogounovitch, T., Mitsutake, N., Mine, M., Shibata, Y., Nakashima, M.,& Yamashita, S.. (2011). Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia. in Endocrine Journal, 58(5), 381-393.
https://doi.org/10.1507/endocrj.K11E-054

Stanojević B, Džodić RR, Saenko V, Milovanović ZM, Pupić G, Živković O, Marković I, Đurišić I, Buta M, Dimitrijević BB, Rogounovitch T, Mitsutake N, Mine M, Shibata Y, Nakashima M, Yamashita S. Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia. in Endocrine Journal. 2011;58(5):381-393.
doi:10.1507/endocrj.K11E-054 .

Stanojević, Boban, Džodić, Radan R., Saenko, Vladimir, Milovanović, Zorka M., Pupić, Gordana, Živković, Ognjen, Marković, Ivan, Đurišić, Igor, Buta, Marko, Dimitrijević, Bogomir B., Rogounovitch, Tatiana, Mitsutake, Norisato, Mine, Mariko, Shibata, Yoshisada, Nakashima, Masahiro, Yamashita, Shunichi, "Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia" in Endocrine Journal, 58, no. 5 (2011):381-393,
https://doi.org/10.1507/endocrj.K11E-054 . .